Amgen Backed Alector Adds $133M
socalTECH
JULY 25, 2018
South San Francisco-based Alector , a biotechnology company focused on finding treatments for neurodegenerative diseases and cancer, announced Wednesday that it has raised $133M in a Series E funding round. The company--which is backed by Thousand Oaks-based Amgen--said the funding came from Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf Venture Partners, Perceptive Advisors, Casdin Capital, Polaris P
Let's personalize your content